A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
== Screening and design == The process of finding a new drug against a chosen target for a particular disease usually involves high-throughput screening (HTS), wherein large libraries of chemicals are tested for their ability to modify the target. For example, if the target is a novel GPCR, compounds will be screened for their ability to inhibit or stimulate that receptor (see antagonist and agonist): if the target is a protein kinase, the chemicals will be tested for their ability to inhibit that kinase. Another function of HTS is to show how selective the compounds are for the chosen target, as one wants to find a molecule which will interfere with only the chosen target, but not other, related targets. To this end, other screening runs will be made to see whether the "hits" against the chosen target will interfere with other related targets – this is the process of cross-screening. Cross-screening is useful because the more unrelated targets a compound hits, the more likely that off-target toxicity will occur with that compound once it reaches the clinic. It is unlikely that a perfect drug candidate will emerge from these early screening runs. One of the first steps is to screen for compounds that are unlikely to be developed into drugs; for example compounds that are hits in almost every assay, classified by medicinal chemists as "pan-assay interference compounds", are removed at this stage, if they were not already removed from the chemical library.
Protein phosphatase 1 subunits PP1β and PP1γ have been shown to form functional complexes with OGT. A synthetic phosphopeptide was able to be dephosphorylated and O-GlcNAcylated by an OGT immunoprecipitate. This complex has been referred to as a "yin-yang complex" as it replaces a phosphate modification with an O-GlcNAc modification. PP1γ also exists in a heterotrimer with OGT and URI under high glucose conditions. MYPT1 is another protein phosphatase subunit that forms complexes with OGT and is itself O-GlcNAcylated. MYPT1 appears to have a role in directing OGT towards specific substrates.
=== Intellectual property === Northwestern University in the US holds the patent on pregabalin, exclusively licensed to Pfizer. That patent, along with others, was challenged by generic manufacturers and was upheld in 2014, giving Pfizer exclusivity for Lyrica in the US until 2018. Pfizer's main patent for Lyrica, for seizure disorders, in the UK expired in 2013. In November 2018, the Supreme Court of the United Kingdom ruled that Pfizer's second patent on the drug, for the treatment of pain, was invalid because there was a lack of evidence for the conditions it covered—central and peripheral neuropathic pain. From October 2015, GPs were forced to change people from generic pregabalin to branded until the second patent ran out in July 2017. This cost the NHS £502 million.
==== Remdesivir/interferon beta-1a ==== In August 2020, the NIAID started the Adaptive COVID‑19 Treatment Trial 3 (ACTT 3) to evaluate the safety and efficacy of a treatment regimen consisting of remdesivir plus interferon beta-1a for hospitalized adults who have a laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation.
== Interactive pathway map == The diagram below shows human protein names. Names in other organisms may differ, and the numbers of isozymes (such as HK1, HK2, ...) likely differ also. Click on genes, proteins and metabolites below to link to respective articles.
Sources: en.wikipedia.org
Different crystalline forms of an element are called allotropes. Some allotropes, particularly those of elements located (in periodic table terms) alongside or near the notional dividing line between metals and nonmetals, exhibit more pronounced metallic, metalloidal or nonmetallic behaviour than others. The existence of such allotropes can complicate the classification of the elements involved. Tin, for example, has two allotropes: tetragonal "white" β-tin and cubic "grey" α-tin. White tin is a very shiny, ductile and malleable metal. It is the stable form at or above room temperature and has an electrical conductivity of 9.17 × 104 S·cm−1 (~1/6th that of copper). Grey tin usually has the appearance of a grey micro-crystalline powder, and can also be prepared in brittle semi-lustrous crystalline or polycrystalline forms. It is the stable form below 13.2 °C and has an electrical conductivity of between (2–5) × 102 S·cm−1 (~1/250th that of white tin). Grey tin has the same crystalline structure as that of diamond. It behaves as a semiconductor (as if it had a band gap of 0.08 eV), but has the electronic band structure of a semimetal. It has been referred to as either a very poor metal, a metalloid, a nonmetal or a near metalloid. The diamond allotrope of carbon is clearly nonmetallic, being translucent and having a low electrical conductivity of 10−14 to 10−16 S·cm−1. Graphite has an electrical conductivity of 3 × 104 S·cm−1, a figure more characteristic of a metal.
15 episodes Rick Stein's Cornwall, Series 2, BBC Two, 2022. 15 episodes Rick Stein's Cornwall, Series 3, BBC Two, 2023. 10 episodes Rick Stein’s Food Stories, BBC Two, February 2024. 15 episodes Rick Stein’s Australia, BBC Two, January 2026. 6 episodes
A study to compare the results of people taking a new treatment with the results of people taking the standard treatment (for example, which group has better survival rates or fewer side effects). In most cases, studies move into phase III only after a treatment seems to work in phases I and II. Phase III trials may include hundreds of people. (NCI) Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. (NLM) Phase 3 studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 studies usually include from several hundred to several thousand subjects. (21CFR312) Phase IV clinical trial
== Marriage == On 29 January 1972, Fred and Rose married. The ceremony took place at Gloucester Register Office, with Fred falsely classifying himself as a bachelor on the marriage certificate. No family or friends were invited. Several months later, with Rose pregnant with her second child, the couple moved from Midland Road to an address nearby: 25 Cromwell Street. Initially the three-storey home, located close to Gloucester city centre, was rented from the council; Fred eventually purchased the property for £7,000 (equivalent to £83,000 in 2025) under the Right to Buy scheme. To facilitate the purchase, many of the upper-floor rooms were initially converted into bedsits to supplement the household income. To maintain a degree of privacy for his own family, Fred installed a cooker and washbasin on the first-floor landing in order that their lodgers need not enter the ground floor where his family lived. Only Fred and his family were permitted access to the back garden of the property. On 1 June 1972, Rose gave birth to a second daughter. The date of her birth led the Wests to name the child Mae June. Rose's first son, Stephen, was born in August 1973.
Sources: en.wikipedia.org
June 18 Iran war: Primary mediator Pakistan states that the signing of the US-Iran memorandum of understanding to end the war implies Tehran will reopen the Hormuz "instantly" and the American blockade of Iranian ports will end "immediately." MV Hondius hantavirus outbreak: Two more passengers who were on the MV Hondius cruise ship during the hantavirus outbreak exit the National Quarantine Unit at the University of Nebraska Medical Center in Omaha, Nebraska, bringing the total number of people remaining in quarantine to six. After over 35 years in service, the U.S. Air Force retires the Boeing VC-25A aircraft used as Air Force One. The Barack Obama Presidential Center is dedicated in Chicago, with all living former presidents except Trump in attendance. June 19 Trump officially unveils the Qatari-gifted Air Force One at Joint Base Andrews. The Department of Justice opens an investigation into Major League Baseball (MLB) after the league warned three San Francisco Giants players for writing Bible verses over their rainbow logo caps before a Pride Night game. June 21 Iran war: Trump issues a threat to invade Iran if they close the Strait of Hormuz, following Iran's claim of its closure due to Israeli strikes in Lebanon. He warns that they "won't even make it back to their fucking country," suggesting a potential threat against Iranian negotiators in Switzerland.
The breeder reactor as its name implies creates larger quantities of 239Pu or 233U (the fissile isotopes) than it consumes. The Clean And Environmentally Safe Advanced Reactor (CAESAR), a nuclear reactor concept that would use steam as a moderator to control delayed neutrons, will potentially be able to use 238U as fuel once the reactor is started with Low-enriched uranium (LEU) fuel. This design is still in the early stages of development.
== Types == There are three distinct Allatostatin types: A, B, and C. Allatostatin C's have 3 subtypes as a result of gene multiplication: C, CC, and CCC. Each Allatostatin type has a unique evolutionary history resulting in distinct conservation and functions across the animal kingdom. Although originally identified in different insects, all three type are found in Drosophila (needs source).
=== Wes: The Meat-Stick Bully === First aired: 24 September 2009 Victim Chris has a problem with a tobacco spittin', hockey playing Texan and self-proclaimed "meat-stick", Wes. Mayhem enlists Tony Bonello to put this bully in his place. He was submitted 4 times and knocked out, but with an illegal head kick. Wes actually managed to knock down Tony Bonello which, apparently, upset the MMA fighter enough for him to break the rules. The kick to the head was hard enough that Wes could not remember where he was, or any of the fight. Because of the illegal kick, the bully received the $5,000 for that round. However, Wes refused it, stating "A knockout's a knockout," and then apologized to Chris by giving the money to him. Mayhem refers to Chris as his favorite victim because he is cute and adorable.
== Causes == The pathophysiology of polymyalgia rheumatica is not well-understood. Evidence shows that there is likely a combined genetic and environmental pathophysiology behind the disease, but concrete identification of the causes, including whether or not polymyalgia rheumatica is an autoimmune disease, remains elusive. It is, at the very least, an immune-mediated disease, with both innate and adaptive immune system elements being known to play a role. Infectious diseases have historically been hypothesized as a likely trigger for disease in genetically susceptible people. Individual studies have sometimes found correlations between specific pathogens and development of the disease, but broader analysis fails to find significant correlations. Proposed causative pathogens, none of which have been proven, include:
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.